HCW Biologics is trading at $1.31, up +6.73%, with no clear catalyst identified for its pre-market move.
- No company-specific announcement for October 20 was identified; the latest release found was October 9, concerning FDA guidance and an IND filing targeted for the first half of 2027.
- Biotech was down pre-market, while major indices were mixed, so those trends do not clearly explain the rise.